|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||N/A - N/A|
|52 Week Range||undefined - undefined|
|PE Ratio (TTM)||N/A|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Merck & Co., Inc.'s (MRK) new products like Keytruda, Zepatier and Bridion are likely to drive sales in Q2. However, headwinds remain in the form genericization of key drugs and increasing competition.
Roche, Celgene and Novartis could change the multiple sclerosis landscape, a sector now dominated by Biogen.
Pharma sector second quarter earnings season has started with industry bellwether Johnson & Johnson (JNJ) reporting earlier this week while AstraZeneca and Merck provided regulatory updates.